Biologics/Approval·FDA Vaccines, Blood & Biologics

BOOSTRIX

MediumPublished May 15, 2026· AI-analyzed May 15, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

The FDA has approved Boostrix for booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 years of age and older.

Who it affects

This approval affects the manufacturer of Boostrix, healthcare providers administering adolescent and adult vaccines, and regulatory professionals managing vaccine labeling and compliance.

Why it matters

This approval confirms the regulatory status of the vaccine as a single-dose booster for a broad age demographic starting at age 10. For regulatory affairs and clinical operations, this necessitates alignment of all prescribing information and promotional materials with the specific age and dosage indications provided.

Practical takeaway

Regulatory teams should update internal labeling records and ensure clinical protocols for booster administration reflect the approved age range of 10 years and older. Quality systems should verify that marketing materials align with the single-dose booster indication.

FDA source material

Boostrix is a product approval indicated for Booster immunization against tetanus, diphtheria and pertussis as a single dose in individuals 10 years of age and older

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

BOOSTRIX

More from Biologics